B.C.’s Bioasis, China’s WuXi Sign Collaboration Deal

Richmond, B.C.-headquartered Bioasis Technologies Inc., a biopharmaceutical company developing a proprietary platform technology for the delivery of therapeutics and the treatment of central nervous system disorders, has signed an initial collaboration for the development and manufacturing of ‘xB3-001’, Bioasis's lead investigational biological candidate to treat brain cancer. Headquartered in Wuxi City, Jiangsu province, China, WuXi Biologics is a leading global platform company providing end-to-end solutions for biologics with a mission to accelerate and transform biologics discovery, development and manufacturing to benefit patients around the world. Through this partnership Bioasis will have access to WuXi Biologics's expertise and technologies from cell line construction and development, cell culture process development, purification process development and formulation development. WuXi Biologics will focus on ensuring that Bioasis's drug product candidates are manufactured with optimal formulation, stability and quality for the clinic.

Use 'AND' or 'OR' to refine your search.

Use quotes " " to get exact matches or remove them to get more results.